DQ113
a potent quinolone, effective against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus and methicillin-susceptible and -resistant coagulase-negative staphylococci; formerly referred to as D61-1113
Also Known As:
D61-1113; DQ 113; DQ-113
Networked: 2
relevant articles (1 outcomes,
0 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
1. | Hirakata, Yoichi:
2 articles
(12/2003 - 12/2003)
|
2. | Kadota, Jun-ichi:
2 articles
(12/2003 - 12/2003)
|
3. | Kohno, Shigeru:
2 articles
(12/2003 - 12/2003)
|
4. | Miyazaki, Yoshitsugu:
2 articles
(12/2003 - 12/2003)
|
5. | Murata, Ikuo:
2 articles
(12/2003 - 12/2003)
|
6. | Tashiro, Takayoshi:
2 articles
(12/2003 - 12/2003)
|
7. | Tomono, Kazunori:
2 articles
(12/2003 - 12/2003)
|
8. | Tsukamoto, Kazuhiro:
2 articles
(12/2003 - 12/2003)
|
9. | Yanagihara, Katsunori:
2 articles
(12/2003 - 12/2003)
|
10. | Fukuda, Yuichi:
1 article
(12/2003)
|
Related Diseases
1. | Infections
12/01/2003
- " Our results suggest that DQ-113 is potent and effective for the treatment of hematogenous pulmonary infections caused by MRSA and VISA strains." 12/01/2003
- " In murine infections caused by PSSP, the 50% effective doses (ED50s) of DQ-113, gatifloxacin, and ciprofloxacin were 6.0, 41.3, and 131.6 mg/kg, respectively. " 12/01/2003
- " Treatment with DQ-113 resulted in a significant decrease in the number of viable bacteria in the lungs of the mice used in the MRSA infection model (counts in mice treated with DQ-113, VCM, and TEIC and control mice, 6.33 +/- 0.22, 7.99 +/- 0.14, 7.36 +/- 0.20, and 8.47 +/- 0.22 log10 CFU/lung [mean +/- standard error of the mean], respectively [P<0.01 for the group treated with DQ-113 compared with the group treated with VCM or TEIC or the untreated group]). " 12/01/2003
- " Effects of DQ-113, a new quinolone, against methicillin- and vancomycin-resistant Staphylococcus aureus-caused hematogenous pulmonary infections in mice." 12/01/2003
- " We compared the effects of DQ-113, a new quinolone, to those of vancomycin (VCM) and teicoplanin (TEIC) in murine models of hematogenous pulmonary infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and VCM-insensitive S. "
|
2. | Pneumonia (Pneumonitis)
|
|
Related Drugs and Biologics